Trials / Completed
CompletedNCT00662818
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
A Multicenter, Randomized, Double-Blind, Placebo- and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stable Vascular Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.
Conditions
- Migraine Disorders
- Heart Disease
- Cerebrovascular Accident
- TIA (Transient Ischemic Attack)
- Vascular Diseases
- Peripheral Vascular Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telcagepant | Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets) |
| DRUG | Acetaminophen/Paracetamol | Acetaminophen/Paracetamol (500 mg X 2 dosage units) |
| DRUG | Placebo to Telcagepant | Placebo 300 mg soft gel capsules or placebo 280 mg tablet. |
| DRUG | Placebo to Acetaminophen/Paracetamol | Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units) |
Timeline
- Start date
- 2008-03-17
- Primary completion
- 2009-09-02
- Completion
- 2009-09-02
- First posted
- 2008-04-21
- Last updated
- 2018-10-19
- Results posted
- 2014-09-17
Source: ClinicalTrials.gov record NCT00662818. Inclusion in this directory is not an endorsement.